Published Studies Related to Atrovent HFA (Ipratropium Cation Inhalation)
Ipratropium bromide HFA. 
Ipratropium bromide is a nonselective antagonist of the muscarinic receptors located on airway smooth muscle, and is delivered via a metered-dose inhaler (MDI). Because of the requirement to phase out chlorofluorocarbon (CFC)-propelled MDIs, the ipratropium bromide inhalation aerosol MDI has been redesigned with a hydrofluoroalkane as the propellant (ipratropium bromide HFA)...
COPD patient satisfaction with ipratropium bromide/albuterol delivered via
Respimat: a randomized, controlled study. 
albuterol HFA (A) metered-dose inhalers as dual monotherapies (I + A)... CONCLUSION: CVT-R is an effective, environmentally friendly inhaler that provides
Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. [2010.02.01]
Ipratropium bromide, an anticholinergic drug used for the treatment of asthma and chronic obstructive pulmonary disease, has low oral bioavailability, but systemic exposure, superior to oral administration, can be achieved by inhalation. Therefore, we investigated the pulmonary absorption mechanism of ipratropium using human bronchial epithelial BEAS-2B cells...
Clinical Trials Related to Atrovent HFA (Ipratropium Cation Inhalation)
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium [Recruiting]
The objective of this study is to assess the daily variation in bronchodilator response to
an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting
anticholinergic (ipratropium) individually and when used in combination in subjects with
Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva [Completed]
To evalute acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in
comparison to placebo when given to COPD patients on pharmacodynamic steady state of
Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease [Completed]
ABSTRACT CONTEXT: Inappropriate antibiotic prescriptions for acute bronchitis is a major
public health concern because of antibiotic resistance. Effective therapies for managing the
symptoms of acute bronchitis are lacking, however.
OBJECTIVE: Determine if patients with acute bronchitis have better symptom control when
treated with inhaled ipratropium.
DESIGN, SETTING, PARTICIPANTS: COUGH STOP was a randomized, double blind, placebo controlled
trial comparing ipratropium with placebo in acute bronchitis. Subjects were referred by
their primary care provider or from urgent care clinics at a single institution. Subjects
had been diagnosed with acute bronchitis and had no significant co-morbidities.
INTERVENTION: Subjects received ipratropium or placebo inhalers, administering 2 puffs four
times daily. A structured telephone interview took place 2, 4, and 8 days after enrollment.
Medical records were reviewed at 60 days.
OUTCOME: The primary endpoint was improvement in cough symptomology; secondary endpoints
included subsequent antibiotic prescriptions and “well being. ” RESULTS: The ipratropium arm
improved significantly (better: 57. 6% day-2, 68. 3% day-4, 91. 9% day-8; c2 (1) = 21. 24, p <
.01) across the 8 days of the telephone survey. This score improved over the same time
period in the placebo arm, however the change was smaller and the difference was not
significant (better: 64. 8% day-2, 74. 6% day-4, 79. 7% day-8; c2 (1) = 4. 69, p =.321). More
than twice as many subjects in the placebo arm received subsequent antibiotic prescriptions
compared to the ipratropium arm (12 vs. 5 respectively), this trend did not meet the
threshold of significance (c2 (1) = 2. 84, p =.076).
CONCLUSION: Patients with acute bronchitis who are otherwise healthy have a more rapid
improvement in their cough symptom score when they are treated with ipratropium, and may be
at decreased risk of unnecessary antibiotic exposure.
Tiotropium Inhalation Capsules and Atrovent MDI Comparison Trial in Taiwan [Completed]
The objective of this study is to compare the bronchodilator efficacy and safety of
tiotropium inhalation capsules (18 mcg once daily) and Atrovent MDI (2 puffs of 20 mcg
q. i.d.) in patients with chronic obstructive pulmonary disease (COPD)
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation [Recruiting]
This is a double blind, controlled clinical trail testing whether three doses of 1. 25 mg of
nebulized levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium
will lead to greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg
of levalbuterol alone every 20 minutes.
The primary hypothesis of this study is that three doses of 1. 25 mg of nebulized
levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium will lead to
greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg of
levalbuterol alone every 20 minutes. The secondary hypothesis is that the treatment
combination of levalbuterol and ipratropium will lead to fewer hospitalizations than
levalbuterol alone in patients with acute asthma exacerbation. Other secondary objectives
include (1) evaluating the relationship between baseline (S)- albuterol levels and (R)-
albuterol levels on presentation and FEV1, (2) the relationship between baseline (S)-
albuterol levels and (R)- albuterol levels on presentation and change in FEV1,(3) time to
event analysis for an improvement of 15%, 20%, 30%, 40%, and 50% in FEV1 from initial
presentation value, (4) analysis of FEV1 at discharge.
Reports of Suspected Atrovent HFA (Ipratropium Cation Inhalation) Side Effects
Oropharyngeal Pain (2),
Oral Discomfort (2),
Drug Effect Decreased (2),
Oral Pain (2), more >>